New drug combo aims to outsmart resistant ovarian cancer

NCT ID NCT04633239

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 43 times

Summary

This early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects. Researchers hope the drug pair can slow or shrink tumors by blocking cancer cell growth and DNA repair.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Los Angeles General Medical Center
RECRUITING

Los Angeles, California, 90033, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Mayo Clinic Hospital in Arizona
ACTIVE_NOT_RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic in Florida
ACTIVE_NOT_RECRUITING

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact

Contact Phone: •••-•••-••••
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
TERMINATED

New York, New York, 10032, United States
Northwestern University
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITING

Irvine, California, 92612, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
UM Sylvester Comprehensive Cancer Center at Coral Gables
ACTIVE_NOT_RECRUITING

Coral Gables, Florida, 33146, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
ACTIVE_NOT_RECRUITING

Deerfield Beach, Florida, 33442, United States
UM Sylvester Comprehensive Cancer Center at Plantation
ACTIVE_NOT_RECRUITING

Plantation, Florida, 33324, United States
USC / Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

Contact

Contact Phone: •••-•••-••••
University of Kansas Cancer Center
SUSPENDED

Kansas City, Kansas, 66160, United States
University of Kansas Cancer Center - Lee's Summit
SUSPENDED

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North
SUSPENDED

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center at North Kansas City Hospital
SUSPENDED

North Kansas City, Missouri, 64116, United States
University of Kansas Cancer Center-Overland Park
SUSPENDED

Overland Park, Kansas, 66210, United States
University of Kansas Clinical Research Center
RECRUITING

Fairway, Kansas, 66205, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Kansas Hospital-Indian Creek Campus
SUSPENDED

Overland Park, Kansas, 66211, United States
University of Kansas Hospital-Westwood Cancer Center
SUSPENDED

Westwood, Kansas, 66205, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
ACTIVE_NOT_RECRUITING

Miami, Florida, 33136, United States
University of Oklahoma Health Sciences Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact

Contact Phone: •••-•••-••••
Wake Forest University Health Sciences
RECRUITING

Winston-Salem, North Carolina, 27157, United States

Contact

Contact Phone: •••-•••-••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

abemaciclib and olaparib

What this could lead to

If it works, this could lead to a new treatment option for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy.

What could go wrong

This is an early phase 1 trial with only 42 participants, so it is too small to prove effectiveness. The combination may cause significant side effects or fail to control the cancer.

Conditions

The condition(s) this trial relates to.

ovarian carcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA